BioSpace News Archive

GERMSTOP(SQ) IS FIRST EVER DISINFECTANT TO KILL HUMAN CORONAVIRUS 229E ON SURFACES FOR UP TO 24 HOURS

GermStopSQ has been issued a Notice of Compliance by Health Canada and granted a Drug Identification Number, making Good Theorem the first to launch a residual* disinfectant that keeps killing 99.999% of bacteria and 99.9% of Human Coronavirus 229E for 24 hours, making it the first of its kind on the market.

January 17, 2023
·
3 min read
Business

Appili Therapeutics Appoints Dr. Carl Gelhaus and Arthur Baran to support the ATI-1701 Biodefense Vaccine Program

Appili Therapeutics has named Dr. Carl Gelhaus as Director of Non-Clinical Research and Arthur Baran as Director of New Product Development for the ATI-1701 program.

January 17, 2023
·
4 min read
Genetown

908 Devices Unveils New Glucose and Lactate On-Line Device for Bioprocess Monitoring and Control

908 Devices Inc. today announced the launch of MAVEN, a device for on-line monitoring and control of glucose and lactate in cell culture and fermentation processes.

January 17, 2023
·
4 min read
Business

Ainos Issues 2023 Shareholder Letter

Ainos, Inc. is pleased to provide the following shareholder letter from Ainos’ Chairman of the Board, President, and Chief Executive Officer, Mr. Chun-Hsien Tsai.

January 17, 2023
·
11 min read
Business

SIGA Technologies Announces Planned Retirement of CEO Phil Gomez in 2023SIGA Board of Directors has initiated search for new CEO

SIGA Technologies, Inc. today announced that Phil Gomez, PhD, Chief Executive Officer of SIGA, has announced his intention to retire as CEO in 2023.

January 17, 2023
·
6 min read
BioMidwest

Akadeum Advances Platform Toward Cell Therapy Applications, New Data Revealed at Biotech Showcase and Development-Stage Automated Instrument Previewing at Advanced Therapies Week

Akadeum Life Sciences Inc. announced today that it will preview its automated platform at Phacilitate’s Advanced Therapies Week, January 17-20th in Miami, Florida.

January 17, 2023
·
3 min read
Drug Development

Theriva Biologics Announces First Patient Dosed in VIRAGE, a Phase 2b Trial of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma

Theriva Biologics today announced the first patient has been dosed in VIRAGE, the Phase 2b randomized, open-label, placebo-controlled, multicenter clinical trial of systemically administered VCN-01 in combination with standard-of-care (SoC) chemotherapy (gemcitabine/nab-paclitaxel) as a first line therapy for patients with newly-diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC).

January 17, 2023
·
6 min read
Policy

180 Life Sciences Engages Kinexum for Assistance in Applying for Marketing Authorisation in the United Kingdom

180 Life Sciences Corp., announced that the Company has engaged Kinexum, a strategic advisory firm, to support the Company in submitting a Marketing Authorisation Application for adalimumab to treat progressive early-stage Dupuytren’s disease.

January 17, 2023
·
7 min read
Business

Immunovia Appoints Lara E. Sucheston-Campbell as Head of Clinical and Medical Affairs to Accelerate Commercial strategy of IMMray™ PanCan-d test in the US market

Immunovia announced that it has appointed Lara E. Sucheston-Campbell as the Head of Clinical and Medical Affairs effective February 1, 2023.

January 17, 2023
·
2 min read
Diamante Closes Euro 595,000 Seed Round Led by Arieli Capital

Diamante S.r.l., a female-led Italian biotechnology company focused on the use of plants for producing high value-added molecules, closes Euro 595K as a second Seed Round led by Arieli Capital.

January 17, 2023
·
4 min read